Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Multiple Myeloma 207Neoplasms, Plasma Cell 73Lymphoma 71Lymphoma, Non-Hodgkin 48Leukemia, Lymphocytic, Chronic, B-Cell 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Leukemia 37Hodgkin Disease 37Lymphoma, Follicular 36Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 34Leukemia, Myeloid, Acute 33Lymphoma, B-Cell, Marginal Zone 32Burkitt Lymphoma 32Myelodysplastic Syndromes 31Lymphoma, Large-Cell, Immunoblastic 31Myeloproliferative Disorders 26Leukemia, Myeloid, Chronic-Phase 22Leukemia, Myeloid, Accelerated Phase 22Blast Crisis 21Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Myelomonocytic, Chronic 16Sezary Syndrome 15Mycosis Fungoides 15Lymphoma, Large-Cell, Anaplastic 15

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteolysis × Plasma cell × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡